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per 1.73 m2, respectively, and the mean serum 
albumin level increased from 1.2 to 3.7, 3.5, and 
3.1 g per deciliter, respectively (Table 1). Aside 
from one transient infusion reaction, none of 
the patients had any serious adverse events dur-
ing the study period.
Ofatumumab may be an effective treatment 
in managing refractory SRNS. Further studies 
are necessary to confirm these observations and 
to define the most effective dose and safety of 
ofatumumab in managing SRNS.
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Thrombotic Microangiopathy Associated with Interferon Beta
To the Editor: Interferon beta is a widely pre-
scribed recombinant-protein therapy with a well-
established favorable safety profile.1 Here, we 
describe an unexpectedly high number of cases 
of thrombotic microangiopathy associated with 
severe or malignant hypertension in four patients 
with multiple sclerosis who were receiving thera-
py with recombinant interferon beta in South 
Scotland. A detailed review of the case histories 
of these patients, including a genetic analysis, 
did not identify any other causal factor for this 
condition, and an analysis of pharmacy records 
revealed a significant association with a com-
mon manufacturing source of interferon beta 
(Rebif, Merck) (Fig. 1, and the Supplementary 
Appendix, available with the full text of this let-
ter at NEJM.org). 
The regulatory authorities in the United King-
dom received six additional spontaneous reports 
of disorders related to thrombotic microangiop-
athy and interferon beta, all associated with the 
same manufacturer (for details, see the Supple-
mentary Appendix). In December 2013, the 
Medicines and Healthcare Products Regulatory 
Agency (MHRA) issued a drug-safety update re-
garding a possible link between interferon beta 
and thrombotic microangiopathy.2 In April 2009, 
the manufacturer of Rebif added a warning to 
the package insert about a possible association 
with thrombotic microangiopathy, which was 
specifically defined as the hemolytic–uremic 
syndrome and thrombotic thrombocytopenic 
purpura (HUS/TTP).
We requested details regarding the geograph-
ical and temporal distribution of the HUS/TTP 
reports. Consistent with our observations in the 
United Kingdom, very few cases were reported 
globally in the first 9 years of safety monitoring. 
However, there has been a recent increase in re-
ports from countries that share the same formu-
lation as that used in the United Kingdom.3 Sub-
stantial caution is required in the interpretation 
of spontaneous reports of adverse drug reactions, 
since such reports are voluntary, are potentially 
subject to underreporting, and may be influenced 
by many factors, including the severity of the 
drug reaction, the diagnostic classification, and 
the degree of publicity. However, we did not de-
tect such patterns or trends in the safe ty data 
from a similar recombinant interferon beta prod-
uct, suggesting that further investigation of the 
association with changes in manufacturing may 
be worthwhile. We have raised these concerns 
with the manufacturer and regulatory authorities.
The patients in our analysis share important 
clinical features (for details, see the Supplemen-
tary Appendix). First, all the patients presented 
after years of well-tolerated treatment with inter-
feron beta, making an association difficult to 
recognize. Second, fulminant presentation was 
associated with severe hypertension. Third, de-
spite the emergency presentation, retrospective 
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review identified chronic changes in all renal-
biopsy specimens and a prodrome in three of the 
four patients with features that included newly 
diagnosed hypertension, hematologic abnormali-
ties, and renal impairment in the months before 
diagnosis. We subsequently identified a similar 
prodrome in a recent fatal case in the United King-
dom. Thrombotic microangiopathy is therefore a 
serious and potentially fatal complication that has 
emerged late in the lifetime of recombinant inter-
feron beta therapy. Early manifestations of this 
complication may be recognizable with increased 
vigilance, with the potential to mitigate severity.
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Figure 1. Cases of Thrombotic Microangiopathy Associated with a Common 
Manufacturing Source of Interferon Beta.
Shown are renal-biopsy specimens obtained from four patients receiving recom-
binant interferon beta therapy in South Scotland in whom thrombotic micro-
angiopathy was diagnosed during an 18-month period (Panels A through D). 
All four specimens show arteriolar luminal obliteration with swollen endo-
thelium and fibrin (arrows; hematoxylin and eosin and silver staining [Panels A, 
B, and D] and Martius scarlet blue [MSB] staining [Panel C]). All four patients 
were treated with recombinant interferon beta from the same manufacturer, 
as confirmed by tracing of drug batches. The Venn diagram shows the over-
lap of 10 batches prescribed to patients in the year before the presentation 
of the index case (Panel E).
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